The DOI matches its Crossref record; 240 of the 241 references it cites were found in a registry or an index.
Dementia in Down syndrome: unique insights for Alzheimer disease research
Open accessAbstract
Virtually all adults with Down syndrome (DS) show the neuropathological changes of Alzheimer disease (AD) by the age of 40 years. This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21. Amyloid-β accumulates in the brain across the lifespan of people with DS, which provides a unique opportunity to understand the temporal progression of AD and the epigenetic factors that contribute to the age of dementia onset. This age dependency in the development of AD in DS can inform research into the presentation of AD in the general population, in whom a longitudinal perspective of the disease is not often available. Comparison of the risk profiles, biomarker profiles and genetic profiles of adults with DS with those of individuals with AD in the general population can help to determine common and distinct pathways as well as mechanisms underlying increased risk of dementia. This Review evaluates the similarities and differences between the pathological cascades and genetics underpinning DS and AD with the aim of providing a platform for common exploration of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is substantial evidence of neuropathology from early in life in DS,6,9,10,21 including defects in neuronal development, an increased ratio of inhibitory to excitatory neurons, alterations in neuronal dendritic spines dynamics, activation of microglia, astrocyte reactivity, and elevated production of inflammatory cytokines in the brain.22,23,24,25”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Individuals with Down syndrome (DS), caused by trisomy of chromosome 21 (chr21, T21), are strongly predisposed to Alzheimer’s disease (AD), due to triplication of the APP gene, with ∼100% penetrance of AD brain pathology by age 40 and variable onset of dementia thereafter.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“People with DS are at greater risk for developing early-onset of dementia caused by AD.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–240 of 240
Dissecting Alzheimer disease in Down syndrome using mouse models
Choong, X. Y., Tosh, J., Pulford, L. J., & Fisher, E. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 41
Sinai, A., Hassiotis, A., Rantell, K. R., & Strydom, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153917 · Cited by 41
The Arizona Cognitive Test Battery for Down Syndrome: Test-Retest Reliability and Practice Effects
Edgin, J. O., Anand, P., Rosser, T. C., Pierpont, E. I., Figueroa, C., Hamilton, D., Huddleston, L. B., Mason, G. M., Spanò, G., Toole, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.215 · Cited by 39
Mégarbané, A., Noguier, F., Stora, S., Manchon, L., Mircher, C., Bruno, R., Dorison, N., Pierrat, F., Rethoré, M. O., Trentin, B., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.24 · Cited by 38
Head, E., Lott, I. T., Hof, P. R., Bouras, C., Su, J., Kim, R., Haier, R. J., & Cotman, C. W. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.9.917 · Cited by 38
Self-citationCerebral amyloid angiopathy in Down's syndrome.
Belza, M. G., & Urich, H. (1986) · PubMed · Cited by 37
Beauchet, O., Allali, G., Thiery, S., Gautier, J., Fantino, B., & Annweiler, C. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03610_9.x · Cited by 37
Progressive myoclonus epilepsy in Down syndrome patients with dementia
On behalf of the Apulian Study Group on Senile Myoclonic Epilepsy, d’Orsi, G., & Specchio, L. M. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7376-x · Cited by 36
Schupf, N., Lee, A., Park, N., Dang, L. T., Pang, D. I., Yale, A., Oh, D. K. T., Krinsky‐McHale, S. J., Jenkins, E. C., Luchsinger, J. A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.020 · Cited by 36
Mortality is associated with apolipoprotein E ɛ4 in nondemented adults with Down syndrome
Zigman, W. B., Jenkins, E. C., Tycko, B., Schupf, N., & Silverman, W. P. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.08.002 · Cited by 33
Stakeholder Buy-In and Physician Education Improve Adherence to Guidelines for Down Syndrome
Santoro, S. L., Martin, L. J., Pleatman, S. I., & Hopkin, R. J. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.12.026 · Cited by 33
Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome
Lao, P. J., Handen, B. L., Betthauser, T. J., Mihaila, I., Hartley, S. L., Cohen, A. D., Tudorascu, D., Bulova, P. D., Lopresti, B. J., Tumuluru, R. V., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170720 · Cited by 32
Pharmacotherapeutic Considerations for Individuals with Down Syndrome
Hefti, E., & Blanco, J. G. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1880 · Cited by 31
Effect of menopause on cognitive performance in women with Down syndrome
Patel, B. N., Seltzer, G. B., Wu, H.-S., & Schupf, N. (2001) · Neuroreport · doi:10.1097/00001756-200108280-00014 · Cited by 30
Rockwood, K. J., Howlett, S. E., Hoffman, D., Schindler, R. J., & Mitnitski, A. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.005 · Cited by 29
Candidate gene analysis for Alzheimer's disease in adults with Down syndrome
Lee, J. H., Lee, A., Dang, L. T., Pang, D. I., Kisselev, S., Krinsky‐McHale, S. J., Zigman, W. B., Luchsinger, J. A., Silverman, W. P., Tycko, B., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.018 · Cited by 29
Iulita, M. F., Caraci, F., & Cuello, A. C. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160321104916 · Cited by 28
Jayaratne, Y. S. N., Elsharkawi, I., Macklin, E. A., Voelz, L., Weintraub, G. S., Rosen, D., & Skotko, B. G. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38399 · Cited by 28
Rodrigues, R., Debom, G. N., Soares, F., Machado, C., Pureza, J., Peres, W., Garcias, G. D. L., Duarte, M. F., Schetinger, M. R. C., Stefanello, F. M., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.03.002 · Cited by 27
Araújo, B. H. S., Torres, L. B., & Guilhoto, L. M. D. F. F. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.10.004 · Cited by 27
Weber, D., Heisig, J., Kneitz, S., Wolf, E., Eilers, M., & Gessler, M. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.11.004 · Cited by 27
Dosage of amyloid precursor protein affects axonal contact guidance in Down syndrome
Sosa, L. J., Postma, N. L., Estrada‐Bernal, A., Hanna, M., Guo, R., Busciglio, J. A., & Pfenninger, K. H. (2013) · The FASEB Journal · doi:10.1096/fj.13-232686 · Cited by 26
Gholipour, T., Mitchell, S. B., Sarkis, R. A., & Chemali, Z. N. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.12.014 · Cited by 25
Chaker, L., Cremers, L. G. M., Korevaar, T. I. M., de Groot, M., Dehghan, A., Franco, O. H., Niessen, W. J., Ikram, M. A., Peeters, R. P., & Vernooij, M. W. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.014 · Cited by 25
Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?
Rohn, T. T., McCarty, K. L., Love, J. E., & Head, E. (2014) · Journal of Parkinson’s Disease and Alzheimer’s Disease · doi:10.13188/2376-922x.1000004 · Cited by 22
Self-citationVariability of .BETA.-Amyloid Protein Deposited Lesions in Down's Syndrome Brains.
Ikeda, S.-I., Tokuda, T., Yanagisawa, N., Kametani, F., Ohshima, T., & Allsop, D. (1994) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.174.189 · Cited by 22
Dick, M. B., Doran, E. W., Phelan, M. J., & Lott, I. T. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000132 · Cited by 22
Self-citationThe Role of Neuropsychology in the Assessment of the Cognitively Impaired Elderly
Lu, P. H., & Lee, G. J. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.002 · Cited by 20
Optimizing health care for individuals with Down syndrome in Israel.
Wexler, I. D., Abu‐Libdeh, A., Kastiel, Y., Nimrodi, A., Kerem, E., & Tenenbaum, A. (2009) · PubMed · Cited by 20
Jenkins, E. C., Marchi, E. J., Velinov, M. T., Ye, L., Krinsky‐McHale, S. J., Zigman, W. B., Schupf, N., & Silverman, W. P. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32575 · Cited by 19
Epigenetics links ageing with Alzheimer disease
Fyfe, I. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.36 · Cited by 18
Cognitive Decline in Down Syndrome—Reply
Lott, I. T., Osann, K., Nelson, L. D., & Doran, E. W. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.1024-a · Cited by 16
Self-citationImproving Memory and Cognition in Individuals with Down Syndrome
Rafii, M. S. (2016) · CNS Drugs · doi:10.1007/s40263-016-0353-4 · Cited by 15
Hom, C. L., Touchette, P. E., Nguyen, V., Fernandez, G., Tournay, A. E., Plon, L., Himber, P., & Lott, I. T. (2014) · Journal of Intellectual Disability Research · doi:10.1111/jir.12123 · Cited by 14
Self-citationObstacle crossing in 7–9-year-old children with Down syndrome
Chen, H., Yu, W.-H., & Yeh, H.-C. (2015) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2015.11.004 · Cited by 14
Blood pressure levels and body mass index in Brazilian adults with Down syndrome
Pucci, F., Machado, G., Solera, E., Cenovicz, F., Arruda, C., Braga, C. Y. Y., & Nisihara, R. (2016) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2016.0057180316 · Cited by 14
Proteolytic Cleavage of Apolipoprotein E in the Down Syndrome Brain
Day, R. J., McCarty, K. L., Ockerse, K. E., Head, E., & Rohn, T. T. (2016) · Aging and Disease · doi:10.14336/ad.2015.1020 · Cited by 10
Self-citationJarrett, S. (2015) · International Journal of Developmental Disabilities · doi:10.1179/2047386914z.00000000094 · Cited by 10
Novel presenilin 1 mutation (p.F386I) in a Chinese family with early-onset Alzheimer's disease
Shea, Y. F., Chan, A. O.-K., Chu, L., Lee, S., Law, C. Y., See, C.-H., Yiu, K.-L., & Chiu, P. K. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.10.015 · Cited by 8
(2012) · PubMed
Self-citation
Research works printed but not linked: 1
- Bertrand, I. & Koffas, D. Cas d’idioti mongolienne adulte avec nombreuses plaques senile et concretions calcaires pallidales. Rev. Neurol. 78, 338 (1946).
Cited by
Sorted by citations
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 483
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Self-citationFortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernández, S., Altuna, M., Pegueroles, J., Montal, V., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30689-9 · Cited by 340
Metadata
- Authors
- Lott, I. T., & Head, E.
- Affiliations
- University of California, Irvine (US)
- University of Kentucky (US)
- Corresponding author
- Lott, Ira T.
- Venue
- Nature Reviews Neurology
- Published
- 2019-02-07
- Volume
- 15
- Issue
- 3
- Pages
- 135-147
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC8061428
- OpenAlex
- W2914706199
- Cited by
- 383
- References
- 241
- Citations by year
- 2026: 35 · 2025: 58 · 2024: 61 · 2023: 45 · 2022: 57 · 2021: 66 · 2020: 46 · 2019: 15
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001414)
- National Institute on Aging (P50AG016573, U01AG051412, U19AG068054, U24AG021886)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD064993)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, Alzheimer's disease, dementia, amyloid precursor protein, APP overexpression, chromosome 21, amyloid-beta deposition, epigenetic factors, disease progression, biomarkers, genetic risk profiles, neuropathology
- MeSH terms
- Alzheimer Disease, Down Syndrome, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
